{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Galectin Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"GALT"},"Address":{"label":"Address","value":"4960 PEACHTREE INDUSTRIAL BOULEVARD,SUITE 240, NORCROSS, Georgia, 30071, United States"},"Phone":{"label":"Phone","value":"+1 678 620-3186"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis."},"CompanyUrl":{"label":"Company Url","value":"https://www.galectintherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ezra R. lowe","title":"Vice President-Clinical & Preclinical Pharmacology"},{"name":"Jessica Kopaczewski","title":"Senior Director-Clinical Operations"},{"name":"Joel Lewis","title":"President, Chief Executive Officer & Director"},{"name":"Khurram Jamil","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}